Conventional Head and Neck cancer treatment with primary surgical intervention is a relatively suffering manipulation because of causing severe facial deformity, and mastication malfunction, and resulted in a very poor quality of life for the patients afterward. And post-operation adjuvant therapy with combined modality treatment with Concurrent Chemo-Radio Therapy (CCRT) has been recommended approach for H&N cancer for decades too. But it is also relatively more toxic to the patient, and further severely disrupts patients’ quality of life due to systemic side-effects caused by intravenous cytotoxic drug delivery. Intra-arterial infusion chemotherapy is another option for CCRT because of not only a better tumor response documented, and also bonus a better quality of life improvement. The demonstrated H&N cancer patient approaching with Intra-Arterial Concurrent Chemo-Radio Therapy (IACCRT) showed a very satisfactory curative outcome. Besides the much better quality of life for the patient was conserved, it also bonuses to restore the patient’s dignity of life when compared to the conventional suffering surgical intervention. Such highly humanize IACCRT treatment modality for H&N cancer patients should be recommended and encouraged in clinical practice.

Medulloblastoma is the most prevalent malignant brain tumor in children, accounting for roughly 15% to 20% of all malignancies of the Central Nervous System (CNS), for 40% of childhood, tumors are in the posterior fossa. Medulloblastoma is a heterogeneous combination of several subgroups with discrete characteristics, rather than a homogeneous illness. Genomic profiling of medulloblastomas revealed that the medulloblastoma may be further divided into four separate molecular subgroups. In this review, we aim to focus on the current state of understanding of the molecularity of the disease with a focus on genomic events that define the aforementioned subgroups and an overview of the molecular subtype of medulloblastoma upon discussing the following points (i) introduction to medulloblastoma and basic classification of the molecular subtype of medulloblastoma followed by their prevalence, age and gender discrimination, and specific molecular characterization. (ii) specific MRI features of the locality of a molecular subtype of medulloblastoma (iii) finally MRI distinguishable features for the identification of the specific molecular type. This review will enhance your knowledge regarding the subtype of medulloblastoma and the role of MRI in the identification of these subtypes.

Rosai-Dorfman disease is an uncommon benign non-Langerhans cell histiocytosis proliferative disorder. It commonly involves the lymph nodes and is classically presented with massive cervical lymphadenopathy. It can also involve the extra-nodal sites of the body and is reported in 43% of Rosai-Dorfman disease cases. The central nervous system is rarely involved in Rosai-Dorfman disease from which intra-cranial is more common than spinal lesions. An isolated dural-based intra-cranial Rosai-Dorfman disease is extremely rare. It usually mimics meningioma on radiological imaging. It is very difficult to diagnose the Rosai-Dorfman disease on imaging and intra-operative appearances of the lesion. We present a histopathologically proven case of an isolated Rosai-Dorfman disease involving the central nervous system in 49 years old female patient which was radiologically mimicking the meningioma.